Imugene Supported by enough cash to fund ops through 2022: Roth Capital Partners

According to Roth Capital Partners, biopharma Company Imugene Limited (ASX:IMU) is suitably funded through enough cash to finance its operations through FY2022. Moreover, the brokerage acknowledged IMU’s clinical progress of multiple vaccines, such as HER-Vaxx and PD1-Vaxx, despite COVID-19-related enrolment headwinds.

The HER-Vaxx trial is targeting HER-2 positive gastric cancer, while the PD1-Vaxx is a vaccine designed to treat tumours such as lung cancer.

Notably, IMU had declared cash reserves of A$32.8 million with zero debt in the previous month.

Further, Roth Capital looks forward to final HER-Vaxx results and the commencement of the clinical programs of oncolytic virus candidates, VAXinia and CHECKvacc, in the US.  





Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK